{"title":"New directions in cancer therapy - HDAC inhibitors","authors":"Stephen Schey FRCP, FRACP, FRCPath","doi":"10.1002/fps.60","DOIUrl":null,"url":null,"abstract":"<p>The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non-Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve Schey considers the place of HDACis in future cancer therapy. Copyright © 2010 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 1","pages":"6-9"},"PeriodicalIF":0.0000,"publicationDate":"2010-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.60","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.60","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non-Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve Schey considers the place of HDACis in future cancer therapy. Copyright © 2010 John Wiley & Sons, Ltd.
癌症治疗的新方向——HDAC抑制剂
HDACis(组蛋白去乙酰化抑制剂)是一类活性药物，已被用于治疗多种肿瘤，包括乳腺癌、前列腺癌、多发性骨髓瘤、甲状腺癌、霍奇金淋巴瘤和非霍奇金淋巴瘤。一种HDAC，伏立诺他，已经获得了FDA的许可，但需要更多的工作来确定和描述这些药物的组蛋白和非组蛋白靶点。在这篇文章中，Steve Schey博士考虑了HDACis在未来癌症治疗中的地位。版权所有©2010 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
